Iradimed (NASDAQ:IRMD) and Intersect ENT (NASDAQ:XENT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.
Risk & Volatility
Iradimed has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Intersect ENT has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.
This table compares Iradimed and Intersect ENT’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and recommmendations for Iradimed and Intersect ENT, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Iradimed currently has a consensus price target of $27.00, suggesting a potential downside of 5.16%. Intersect ENT has a consensus price target of $39.40, suggesting a potential upside of 29.14%. Given Intersect ENT’s higher probable upside, analysts plainly believe Intersect ENT is more favorable than Iradimed.
Earnings and Valuation
This table compares Iradimed and Intersect ENT’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Intersect ENT||$96.30 million||9.65||-$16.36 million||($0.56)||-54.48|
Iradimed has higher earnings, but lower revenue than Intersect ENT. Intersect ENT is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
19.9% of Iradimed shares are owned by institutional investors. Comparatively, 90.3% of Intersect ENT shares are owned by institutional investors. 61.2% of Iradimed shares are owned by company insiders. Comparatively, 5.9% of Intersect ENT shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Iradimed beats Intersect ENT on 10 of the 14 factors compared between the two stocks.
IRadimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its MRI compatible products through direct sales force and independent distributors. IRadimed Corporation was incorporated in 1992 and is headquartered in Winter Springs, Florida.
About Intersect ENT
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. The company is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.